Loading...

Lonza Group AG

LZAGYPNK
Healthcare
Medical - Diagnostics & Research
$67.66
$1.18(1.77%)

Lonza Group AG (LZAGY) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Lonza Group AG (LZAGY), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
-2.13%
2.13%
Operating Income Growth
9.55%
9.55%
Net Income Growth
-2.75%
2.75%
Operating Cash Flow Growth
-8.01%
8.01%
Operating Margin
14.66%
14.66%
Gross Margin
32.86%
32.86%
Net Profit Margin
9.67%
9.67%
ROE
6.81%
6.81%
ROIC
5.97%
5.97%

Lonza Group AG (LZAGY) Income Statement & Financial Overview

Explore comprehensive income reports for Lonza Group AG LZAGY, broken down by year and quarter.

MetricQ4 2024Q2 2024Q4 2023Q2 2023
Revenue$3.52B$3.06B$3.64B$3.08B
Cost of Revenue$2.47B$1.94B$2.80B$1.97B
Gross Profit$1.04B$1.12B$840.00M$1.11B
Gross Profit Ratio$0.30$0.37$0.23$0.36
R&D Expenses$0.00$0.00$194.00M$0.00
SG&A Expenses$574.00M$540.00M$138.00M$497.00M
Operating Expenses$574.00M$582.00M$138.00M$497.00M
Total Costs & Expenses-$3.05B$2.52B$2.94B$2.47B
Interest Income$0.00$0.00$27.00M$24.00M
Interest Expense$68.00M$52.00M$28.00M$31.00M
Depreciation & Amortization$336.00M$273.00M$320.00M$301.00M
EBITDA$764.00M$824.00M$1.02B$899.00M
EBITDA Ratio$0.22$0.27$0.28$0.30
Operating Income$470.00M$534.00M$702.00M$611.00M
Operating Income Ratio$0.13$0.17$0.19$0.20
Other Income/Expenses (Net)-$110.00M-$139.00M-$398.00M-$125.00M
Income Before Tax$360.00M$395.00M$304.00M$499.00M
Income Before Tax Ratio$0.10$0.13$0.08$0.16
Income Tax Expense$52.00M$65.00M$60.00M$75.00M
Net Income$307.00M$329.00M$244.00M$410.00M
Net Income Ratio$0.09$0.11$0.07$0.13
EPS$4.35$4.61$3.38$5.52
Diluted EPS$4.14$4.61$3.36$5.52
Weighted Avg Shares Outstanding$70.64M$71.37M$72.12M$74.28M
Weighted Avg Shares Outstanding (Diluted)$74.12M$71.37M$72.70M$74.28M

Over the past four quarters, Lonza Group AG demonstrated steady revenue growth, increasing from $3.08B in Q2 2023 to $3.52B in Q4 2024. Operating income reached $470.00M in Q4 2024, maintaining a consistent 13% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $764.00M, reflecting operational efficiency. Net income dropped to $307.00M, with EPS at $4.35. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;